Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy

NCT05298722 is registered in ClinicalTrials.gov with University Hospital, Ghent as lead sponsor.

NCT NCT05298722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05298722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy
Lead sponsor
University Hospital, Ghent
Phase
Not applicable
Overall status
Recruiting
Start date
December 12, 2022
Completion date
March 31, 2028
Enrollment
45 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer